Clinical Trial Update: A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial (ATTAIN-Outcomes) evaluating Orforglipron (LY3502970) for cardiovascular outcomes in adults with atherosclerotic cardiovascular disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Chronic Kidney Disease

Drugs mentioned

• Orforglipron (orforglipron)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease | Phase 3 | Status: RECRUITING